Rabies
Conditions
Brief summary
The purpose of this clinical trial is to investigate the safety and tolerability of IM administered CV8102 and an IM administered combination of CV8102 and rabies vaccine in humans.
Interventions
Sponsors
CureVac
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Compliant with protocol procedures and available for clinical F/U until the protocol-defined end of the trial 2. Physical examination and laboratory results without clinically significant findings 3. Body Mass Index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 4. Subjects must use reliable forms of contraception (barrier method with spermicidal agent or true abstinence) and must refrain from sperm donation during treatment and the 4-week F/U period after the last treatment.
Exclusion criteria
1. Use of any investigational or non-registered product (adjuvant, drug) other than CV8102 within 4 weeks preceding the administration of the CV8102, or planned use of any such agent during the trial period 2. Subject has received any licensed or non-licensed vaccines within 4 weeks prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine or planned vaccinations during the trial period 3. Any treatment with immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine. The use of inhaled and nasal steroids, as well as topical steroids outside the vaccination area, will be permitted 4. Any medically diagnosed or suspected immune deficient condition based on medical history and physical examination 5. History of autoimmune disease or suspected autoimmune disease based on medical history and physical examination that cannot be ruled out based on further examinations 6. Administration of immunoglobulins (Igs) and/or any blood products within the 3 months preceding the administration of CV8102 or licensed rabies vaccine 7. Acute disease at the time of enrolment. Acute disease is defined as the presence of any acute condition including but not limited to non-febrile or febrile common colds, urinary tract infections, inflammatory, allergic or traumatic conditions that may interfere with safety assessment of the investigational products 8. Presence or evidence of significant acute or chronic disease, in particular heart disease including coronary artery disease and chronic pulmonary diseases (e.g., chronic obstructive pulmonary disease \[COPD\]); uncontrolled medical or psychiatric illness (subjects with uncomplicated chronic diagnoses stable and treated for ≥ 3 months e.g., mild hypertension well-controlled with medication, may be enrolled - provided the condition and its therapy are known not to be associated with an immunocompromised state or an autoimmune disease) 9. Major congenital defects 10. Known allergy to any component (or closely related substance) of the licensed rabies vaccine product 11. Known type I allergy to beta-lactam antibiotics 12. Evidence of current alcohol or drug abuse 13. History of any neurological disorders or seizures 14. Known seropositivity for human immunodeficiency virus (HIV), hepatitis B virus (HBV) (except in subjects previously vaccinated against HBV) or hepatitis C virus (HCV) 15. Foreseeable non-compliance with protocol as judged by the Investigator 16. History of any life-threatening anaphylactic reactions 17. Subjects with impaired coagulation in whom an IM injection is contraindicated. Additional
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of subjects with serious and non serious adverse events | Up to 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose (MTD) of CV8102 within the dose range of 25 µg to 250 µg. | Up to day 49 | — |
| MTD of CV8102 in combination with rabies vaccine | Up to Day 49 | — |
| Vaccination-elicited serum rabies VNTs among the dose groups | Up to day 35 | — |
| Vaccination-elicited innate and adaptive immune responses | Up to Day 35 | Evaluation of corresponding serum and blood parameters (e.g. relevant cytokines, chemokines, immune effector molecules and lymphocyte phenotyping) |
Countries
Germany
Outcome results
None listed